Evidence map›Paper›PMID 21781305›Full record

ArticleBMC biotechnology2011

The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19).

Jianguo Shi, Richard S McIntosh, Jaime Adame-Gallegos, Prabhjyot K Dehal, Marjolein van Egmond, Jan van de Winkel, Simon J Draper, Emily K Forbes, Patrick H Corran, Anthony A Holder and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Susceptibility toFrontiers in immunology · 2020
    Article
  5. Article
  6. Article
  7. Neutrophils and Malaria.Frontiers in immunology · 2018
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Jianguo ShiInstitute of Genetics, Queen's Medical Centre, University of Nottingham, NG7 2UH, UK.
Richard S McIntosh
Jaime Adame-Gallegos
Prabhjyot K Dehal
Marjolein van Egmond
Jan van de Winkel
Simon J Draper
Emily K Forbes
Patrick H Corran
Anthony A Holder
Jenny M Woof
Richard J Pleass
Jenner Institute · GBNinewells Hospital · GBQueen's Medical Centre · GBUniversity of Nottingham · GBAmsterdam UMC Location VUmc · NLLondon School of Hygiene & Tropical Medicine · GBUniversity Medical Center Utrecht · NL

Funding

Medical Research Council G0300145Medical Research Council G1000527Medical Research Council G1000527(95710)Medical Research Council MC_U117532067
6 · The paper itself

Abstract

backgroundHuman immunoglobulin G (IgG) plays an important role in mediating protective immune responses to malaria. Although human serum immunoglobulin A (IgA) is the second most abundant class of antibody in the circulation, its contribution, if any, to protective responses against malaria is not clear.

resultsTo explore the mechanism(s) by which IgA may mediate a protective effect, we generated fully human IgA specific for the C-terminal 19-kDa region of Plasmodium falciparum merozoite surface protein 1 (PfMSP1 19), a major target of protective immune responses. This novel human IgA bound antigen with an affinity comparable to that seen for an epitope-matched protective human IgG1. Furthermore, the human IgA induced significantly higher NADPH-mediated oxidative bursts and degranulation from human neutrophils than the epitope-matched human IgG1 from which it was derived. Despite showing efficacy in in vitro functional assays, the human IgA failed to protect against parasite challenge in vivo in mice transgenic for the human Fcα receptor (FcαRI/CD89). A minority of the animals treated with IgA, irrespective of FcαRI expression, showed elevated serum TNF-α levels and concomitant mouse anti-human antibody (MAHA) responses.

conclusionsThe lack of protection afforded by MSP1 19-specific IgA against parasite challenge in mice transgenic for human FcαRI suggests that this antibody class does not play a major role in control of infection. However, we cannot exclude the possibility that protective capacity may have been compromised in this model due to rapid clearance and inappropriate bio-distribution of IgA, and differences in FcαRI expression profile between humans and transgenic mice.

Indexed as

AnimalsAntibodies, ProtozoanAntigens, CDDisease Models, AnimalHumansImmunization, PassiveImmunoglobulin AImmunoglobulin GMalariaMerozoite Surface Protein 1MiceMice, TransgenicNADPH OxidasesPlasmodium bergheiPlasmodium falciparumReceptors, FcAntibodies, ProtozoanAntigens, CDFc(alpha) receptorImmunoglobulin AImmunoglobulin GMerozoite Surface Protein 1NADPH OxidasesReceptors, FcRecombinant ProteinsTumor Necrosis Factor-alpha

Identifiers

PMID21781305
PMCPMC3199766
OpenAlexW2087516643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.